VAISHALIVaishali Pharma Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-10-30 (delayed ~30 min in market hours)
Vaishali Pharma Limited engages in the pharmaceutical business in India and internationally. It offers a portfolio of active pharmaceutical ingredients, such as antibiotics, anti-ulcer, anti-inflammatory, analgesic, anti-pyretic, topical steroids, antimalarial, cardiac, corticosteroids, anti-diabetics, anti-cold, anti-allergic, anti-diarrheal, anti-protozoal, anti-parasitic, excipients, anti-viral, anti-epileptic, anti-asthmatic, enzymes, anti-fungal, anti-platelet agent, skeletal muscle relaxant, and anti-helminitic. The company also provides formulations, including antibiotics, antibacterial, anti-platelet, laxative, anti-ulcer, enzymes, anti-asthmatic, anti-malarial, anti-cold, anti-allergic, anti-viral, anti-psychotic, anti-fungal, vitamins, topical steroids, corticosteroids, anti-inflammatory, analgesic, anti-pyretic, anti-diabetic, cardiac, and other products. In addition, it offers disposable surgical and casting tape products; herbal products; veterinary products; nutraceutical products; and oncology products. The company was formerly known as Vaishali Pharma Private Limited. Vaishali Pharma Limited was founded in 1989 and is based in Mumbai, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on VAISHALI — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
Why avoid
- • Overall evidence is weak (AlgoScore 22/100)
- • Revenue growth: -3.6% YoY
- • ROE: 5.8%
- • RSI: 25
- • MACD: bearish
Bull case
- • Profit growth: 18.5% YoY
- • Debt/Equity: 0.27
- • Golden cross setup: SMA50 above SMA200
Bear case
- • Revenue growth: -3.6% YoY
- • ROE: 5.8%
- • RSI: 25
- • MACD: bearish
Key risks
- • Elevated volatility / drawdown profile — size positions accordingly
- • Weak fundamentals — technical strength may not sustain
- • Momentum is fading versus the broader market
- • Revenue growth: -3.6% YoY
- • ROE: 5.8%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹0.55). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.